Genome-wide DNA Methylation, Transcriptomic, and Whole Exome Sequencing Data from Baseline FFPE Tumour Biopsies of Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICI) have transformed the treatment of advanced non-small cell lung cancer (NSCLC); however, response rates remain low and current biomarkers such as PD-L1 expression and tumor mutational burden (TMB) show limited predictive accuracy. This study investigated how baseline molecular profiles impact ICI response in a real-world cohort of advanced NSCLC patients. Multi-omics data were generated from diagnostic formalin-fixed paraffin-embedded (FFPE) primary tumor biopsies of 32 advanced NSCLC patients treated with anti-PD1/PD-L1 therapy in a real-world clinical setting. Genome-wide DNA methylation profiling was performed using the Illumina Infinium MethylationEPIC array (n=32). Transcriptomic profiling was conducted by bulk RNA sequencing (n=30). Somatic mutational profiling was obtained by whole exome sequencing (WES) using matched peripheral blood mononuclear cells (PBMCs) as germline controls (n=15). ICI response was assessed by computed tomography scan at 3 and 6 months after the first ICI dose according to RECIST 1.1 criteria.
- Type: Other
- Archive: European Genome-phenome Archive (EGA)
| Publications | Citations |
|---|---|
|
Epigenetic repression of oncogenic signaling defines immune-permissive tumor states associated with response to immune checkpoint inhibitors in advanced NSCLC.
J Immunother Cancer 14: 2026 e015745 |
0 |
